Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis
JAMA Neurology · 2026
DOI: 10.1001/jamaneurol.2026.2500 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JAMA Neurology, 2026. Verfasst von Maximilian Einsiedler und 59 weiteren Autor:innen. Beteiligte Einrichtung: Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience, Neurology Departments of Biomedicine and Clinical Resear…. Hauptthemen laut MEDLINE: Glial Fibrillary Acidic Protein, Disease Progression, Multiple Sclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Capturing individual multiple sclerosis (MS) progression is difficult; few studies have evaluated glial fibrillary acidic protein (GFAP) in large longitudinal cohorts with independent validation.
Objective
To investigate whether serum GFAP levels and treatment-related changes are associated with future progression independent of relapse activity (PIRA). Design, Setting, and Participants This was a prospective observational study using 2 large MS cohorts: the Swiss MS Cohort (SMSC; initiated in June 2012; data extraction September 22, 2025) and the Expression, Proteomics, Imaging, Clinical study (EPIC; initiated in July 2004; data extraction February 21, 2024). The study took place at tertiary MS centers (8 for SMSC and 1 for EPIC). A total of 2329 persons with MS from both cohorts with at least 1 available time point with neurofilament light chain (NfL) and GFAP measurements were included (overall 18 629 measurements). Exposures Clinical data and NfL and GFAP z scores, collected and calculated every 6 or 12 months. Main Outcomes and Measures Risk of future PIRA, defined as Expanded Disability Status Scale score worsening confirmed after 6 or more months without relapses (in SMSC), or a composite additionally including greater than 20% worsening in the 9-hole peg test or timed 25-ft walk test (in EPIC).
Results
The SMSC and EPIC cohorts consisted of 1709 (13 375 samples; median [IQR] follow-up, 6.9 [2.5-10.7] years and age, 40.6 [32.1-50.1] years; 1128 [66.0%] female) and 620 (5254 samples; median [IQR] follow-up, 13.1 [9.4-14.0] years and age, 42.0 [35.0-50.0] years; 432 [69.7%] female) persons with MS, respectively. Consistent with prior work, high NfL was associated with relapse risk within the next year, whereas high GFAP was associated with long-term PIRA risk. In addition, elevated GFAP ( z score >1.0 [84th percentile]) was associated with an average 40% higher hazard of short-term PIRA in the subsequent visit interval (SMSC: median [IQR] 346 [190-375] days; hazard ratio [HR], 1.45, 95% CI, 1.21-1.75; P < .001; EPIC: 385 [355-518] days; HR, 1.36; 95% CI, 1.07-1.71; P = .01). GFAP-based cohort enrichment in clinical trials targeting PIRA as an end point could reduce sample size by approximately 20%. Further, in SMSC, every yearly GFAP z score unit reduction during the first 2 years receiving fingolimod or B-cell–depleting therapy was associated with a lower risk of subsequent PIRA (54% risk reduction; HR, 0.46; 95% CI, 0.26-0.84; P = .01 and 67% risk reduction; HR, 0.33; 95% CI, 0.18-0.61; P < .001), respectively. Conclusions and Relevance In this cohort study, elevated GFAP was associated with a higher risk of PIRA, while treatment-associated reductions were associated with a lower PIRA risk. Together, these results suggest that serum GFAP may serve as a biomarker for personalized risk stratification and treatment monitoring and as a screening tool to reduce cohort size in clinical trials targeting MS progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience, Neurology Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
- Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco.
- Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.
- IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
- Translational Imaging in Neurology Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital and University of Basel, Basel, Switzerland.
- Dipartimento di Scienze della Salute, Università degli Studi di Genova, Genoa, Italy.
Zitieren
APA
Einsiedler, M., Sandgren, S., Schaedelin, S., Ning, K., Maleska Maceski, A., Oechtering, J., Cordano, C., Melie-Garcia, L., Gelfand, J. M., Cagol, A., Henry, R. G., Finkener, S., Lalive, P. H., Müller, S., Pot, C., Mathias, A., Du Pasquier, R., Hoepner, R., Chan, A., …, & Kana, V. (2026). Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2026.2500
Vancouver
Einsiedler M, Sandgren S, Schaedelin S, Ning K, Maleska Maceski A, Oechtering J, et al. Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis. JAMA Neurology. 2026. doi:10.1001/jamaneurol.2026.2500
BibTeX
@article{Einsiedler2026,
author = {Einsiedler, Maximilian and Sandgren, Sofia and Schaedelin, Sabine and Ning, Kiarra and Maleska Maceski, Aleksandra and Oechtering, Johanna and Cordano, Christian and Melie-Garcia, Lester and Gelfand, Jeffrey M and Cagol, Alessandro and Henry, Roland G and Finkener, Sebastian and Lalive, Patrice H and Müller, Stefanie and Pot, Caroline and Mathias, Amandine and Du Pasquier, Renaud and Hoepner, Robert and Chan, Andrew and Disanto, Giulio and Zecca, Chiara and D'Souza, Marcus and Hemkens, Lars G and Yaldizli, Özgür and Fischer-Barnicol, Bettina and Derfuss, Tobias and Roth, Patrick and Herwerth, Marina and Gobbi, Claudio and Brassat, David and Tackenberg, Björn and Pedotti, Rosetta and Wiendl, Heinz and Berger, Klaus and Hermesdorf, Marco and Arrambide, Georgina and Piehl, Fredrik and Zetterberg, Henrik and Cree, Bruce A C and Sormani, Maria Pia and Kappos, Ludwig and Hauser, Stephen L and Khalil, Michael and Granziera, Cristina and Green, Ari J and Leppert, David and Benkert, Pascal and Abdelhak, Ahmed and Kuhle, Jens and Expression, Proteomics, Imaging, Clinical (EPIC) study and the Swiss MS Cohort (SMSC) investigators, Expression, Proteomics, Imaging, Clinical (EPIC) study and the Swiss MS Cohort (SMSC) investigators and Hofer, Lisa and Hughes, Michelle and Genc, Nafiye and Zadic, Amar and Vilchez Gomez, Juan Francisco and Galbusera, Riccardo and Galli, Edoardo and Müller, Jannis and Uginet, Marjolaine and Kana, Veronika},
title = {Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis},
journal = {JAMA Neurology},
year = {2026},
doi = {10.1001/jamaneurol.2026.2500}
}
EUVIMED